Alnylam partners with Roche on zilebesiran; receives $310M upfront, up to $2.5B milestones

ALNYLAM PHARMACEUTICALS, INC.

Upfront cash payment of $310 million; potential total deal value up to $2.8 billion including development, regulatory, and sales milestones.
Alnylam and Roche to co-develop and co-commercialize zilebesiran in US (50/50 profit share); Roche gets exclusive ex-US rights with low double-digit royalties.
Alnylam leads joint clinical development plan including cardiovascular outcomes trial; development costs split 40% Alnylam, 60% Roche.
Zilebesiran is an investigational RNAi therapeutic for hypertension, currently in Phase 2; Phase 1 showed durable blood pressure reduction up to 6 months.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ALNYLAM PHARMACEUTICALS, INC. entered into Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. valued at $310 million (effective 2023-07-21).

Action: entry
Agreement: collaboration
Counterparty: F. Hoffmann-La Roche Ltd. and Genentech, Inc.
Value: $310 million
Effective: 2023-07-21

Exact text from the filing

On July 21, 2023 (the “ Effective Date ”), Alnylam Pharmaceuticals, Inc. (the “ Company ”), entered into a Collaboration and License Agreement (the “ Agreement ”) with F. Hoffmann-La Roche Ltd. (“ Roche Basel ”) and Genentech, Inc. (“ Genentech ,” each of Roche Basel and Genentech, individually and collectively, “ Roche ”)

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-194715

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.